MRK.BA : Summary for MERCK & CO INC CEDEAR (10 REP 1 - Yahoo Finance

U.S. Markets closed

Merck & Co., Inc. (MRK.BA)


Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
98.700.00 (0.00%)
At close: 4:07PM ART
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close98.70
Open98.70
Bid98.70 x
Ask0.00 x
Day's Range98.70 - 98.70
52 Week Range97.55 - 105.00
Volume3,000
Avg. Volume376
Market Cap2.56T
BetaN/A
PE Ratio (TTM)70.00
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Market Realist43 minutes ago

    Eli Lilly’s Valuation Compared to Its Peers’

    Eli Lilly and Company (LLY) is a US pharmaceutical company headquartered in Indianapolis, Indiana. LLY deals with both human pharmaceuticals and animal health.

  • Reuters12 hours ago

    UPDATE 2-Roche MS drug Ocrevus approved by FDA after 3-month delay

    The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).

  • Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma
    Zacks2 days ago

    Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma

    Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).